Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER vs ADALAT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It causes vasodilation and decreases systemic vascular resistance.
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
Short-term treatment of hypertension when oral therapy is not feasible or desirable,Management of severe hypertension (off-label)
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Intravenous infusion: initial dose 5 mg/hour, titrate by 2.5-5 mg/hour every 15-30 minutes as needed; maximum 15 mg/hour. Oral: 20 mg three times daily initially, then 30-40 mg three times daily.
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
2 to 4 hours in healthy subjects; increased in hepatic impairment (up to 7 hours) and in elderly. No significant change in renal impairment.
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Extensively metabolized in the liver via cytochrome P450 (CYP) enzymes, primarily CYP3A4 and CYP2C8, to inactive metabolites.
Hepatic via CYP3A4; extensive first-pass metabolism; metabolites are inactive.
Primarily hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites accounts for approximately 60-70% of total elimination, with renal excretion of metabolites approximately 30-40%.
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
>95% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
92-98% bound to plasma proteins (albumin and alpha-1-acid glycoprotein)
8.4 L/kg (0.084 L/kg for a 70 kg adult? Please check: typical Vd is 8.4 L/kg? Actually nicardipine Vd is about 8.4 L/kg, which is large, indicating extensive tissue distribution). Correct: Vd = 8.4 L/kg (range 0.6-8.4 L/kg? Standard value is ~8.4 L/kg).
0.8-1.2 L/kg. Clinical meaning: indicates extensive tissue distribution, consistent with high lipophilicity.
Oral: 35% (extensive first-pass metabolism); intravenous: 100%.
Oral immediate-release: 45-60% (due to first-pass metabolism); extended-release: 60-85% (due to slower release and reduced first-pass effect).
Cr Cl 30-50 m L/min: maximum IV infusion rate 8 mg/hour; Cr Cl <30 m L/min: maximum IV infusion rate 5 mg/hour. Oral: no adjustment specified but monitor closely.
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, use with caution and reduce initial dose by 50%.
Child-Pugh Class A: start with 50% of usual dose; Class B: start with 25% of usual dose; Class C: avoid use or use extreme caution.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce by 75%.
Limited data; for IV infusion, start at 0.5 mcg/kg/min and titrate to effect; typical range 0.5-5 mcg/kg/min. Oral: 0.5-1 mg/kg/dose three times daily (max 30 mg/dose).
0.25-0.5 mg/kg/dose orally every 6-8 hours; maximum 3 mg/kg/day. Extended-release not recommended.
Start at lower end of dosing range; IV infusion initial rate 3 mg/hour; oral initial dose 20 mg twice daily; monitor blood pressure closely.
Start at 10 mg orally twice daily; titrate slowly due to increased sensitivity and risk of hypotension.
None
None
Use caution in patients with coronary artery disease due to risk of increased angina or myocardial infarction,May cause hypotension, hepatic impairment, and elevated liver enzymes,May exacerbate congestive heart failure,Use with caution in patients with impaired renal function,Monitor blood pressure and heart rate during infusion
May cause hypotension, especially in patients on beta-blockers or with poor cardiac reserve,Risk of increased angina and/or myocardial infarction upon initiation or dose increase,Peripheral edema,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hepatic impairment,Exacerbation of angina on withdrawal
Hypersensitivity to nicardipine or any component of the formulation,Advanced aortic stenosis (may reduce coronary perfusion),Lactation (use not recommended)
Hypersensitivity to nifedipine,Cardiogenic shock,Significant aortic stenosis,Concurrent use with rifampin,Pregnancy (category C)
Grapefruit and grapefruit juice may increase nicardipine levels; avoid concurrent use. No other significant food interactions. Maintain a heart-healthy, low-sodium diet as recommended for hypertension management.
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 and increase nifedipine serum concentrations, leading to enhanced hypotensive effects and risk of toxicity. Grapefruit interaction persists for 24 hours; separate consumption by at least 4 hours if unavoidable, but preferable to avoid entirely. Avoid alcohol which can increase hypotension. High-fat meals may reduce absorption of extended-release formulations; take consistently with or without food.
NICARDIPINE (CARDENE) is a calcium channel blocker. Animal studies (rats, rabbits) showed embryotoxicity, fetotoxicity, and teratogenicity at doses ≥10× human dose. In humans, no adequate controlled studies; first trimester: potential for teratogenic risk (class C). Second and third trimesters: may cause fetal hypoxia, metabolic acidosis, and hypotension due to maternal hypotension. Use only if benefit outweighs risk.
First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibition. Category C.
NICARDIPINE is excreted in human milk. M/P ratio not reported. Limited data suggest low concentrations; however, potential for adverse effects in infant. Caution advised; consider alternative if possible.
Excreted in breast milk; M/P ratio ~0.85. Consider risks versus benefits; monitor infant for hypotension.
No specific dose adjustment guidelines for pregnancy; however, increased clearance and volume of distribution in pregnancy may necessitate higher doses. Start with lowest effective dose; titrate carefully to avoid maternal hypotension and fetal distress.
No standard dose adjustment; monitor clinical response and blood pressure; may require lower doses due to vasodilation effects.
Cardene (nicardipine) IV infusion in D5W is a dihydropyridine calcium channel blocker used for short-term treatment of hypertension when oral therapy is not feasible. It is photosensitive; protect from light. Administer via central line due to peripheral vein irritation. Titrate based on blood pressure response; onset within minutes. Use with caution in patients with severe aortic stenosis, heart failure, or hepatic impairment. Avoid in patients with advanced aortic stenosis due to risk of reducing coronary perfusion.
Adalat (nifedipine) is a dihydropyridine calcium channel blocker. Use immediate-release capsules only for hypertensive emergencies, not chronic treatment due to risk of reflex tachycardia and unpredictable hypotension. Extended-release formulations are preferred for stable angina and hypertension. Avoid grapefruit juice as it increases nifedipine levels via CYP3A4 inhibition. Monitor for peripheral edema, gingival hyperplasia, and constipation. Contraindicated in cardiogenic shock, severe aortic stenosis, and within 4 weeks of myocardial infarction.
This medication is given intravenously to lower blood pressure quickly.,Your blood pressure and heart rate will be monitored closely during infusion.,Report any pain, redness, or swelling at the IV site immediately.,Avoid sudden position changes to prevent dizziness or fainting.,Do not stop the infusion without medical guidance.,Inform your healthcare provider if you have liver disease, heart failure, or aortic stenosis.
Swallow extended-release tablets whole; do not crush, chew, or split.,Avoid grapefruit and grapefruit juice while taking this medication.,Report persistent swelling of ankles/feet, gum tenderness or bleeding, or severe dizziness.,Do not stop abruptly; taper under medical supervision to avoid rebound hypertension.,Take at the same time each day; if a dose is missed, skip it if near next dose.,May cause dizziness; avoid driving until you know how it affects you.,Increase fluid and fiber intake to prevent constipation.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER vs ADALAT, answered by our medical review team.
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER is a Calcium Channel Blocker that works by Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It causes vasodilation and decreases systemic vascular resistance.. ADALAT is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER and ADALAT depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER is: Intravenous infusion: initial dose 5 mg/hour, titrate by 2.5-5 mg/hour every 15-30 minutes as needed; maximum 15 mg/hour. Oral: 20 mg three times daily initially, then 30-40 mg three times daily.. The standard adult dose of ADALAT is: 10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER and ADALAT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER is classified as Category C. NICARDIPINE (CARDENE) is a calcium channel blocker. Animal studies (rats, rabbits) showed embryotoxicity, fetotoxicity, and teratogenicity at doses ≥10× human dose. In humans, no a. ADALAT is classified as Category C. First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibiti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.